Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Exelon Clear all
Terminated Not applicable Interventional Results available

Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

NCT01602198
View directory record Official record
Conditions
Mild Cognitive Disorder, Mild Cognitive Impairment
Interventions
Exelon [rivastigmine] transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
55 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

NCT00018278
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Aricept, Exelon, Nicoderm Patch
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2001
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Cognitive Decline in Non-demented PD

NCT01340885
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Strattera, Exelon, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2020 · Synced Sep 2, 2026, 5:20 AM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional

Safety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer's Disease

NCT00305903
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine, memantine
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Paterson, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 20, 2007 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 2, 2026, 5:20 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Feasibility (TADF)

NCT04732182
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
BrightGo cognitive training, Standard of Care medication for early Alzheimer's Disease
Device · Drug
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Brunswick, New Jersey • North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 1, 2022 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional

Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)

NCT00000174
View directory record Official record
Conditions
Alzheimer Disease, Cognition Disorders
Interventions
Rivastigmine
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Peoria, Arizona • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

NCT03840837
View directory record Official record
Conditions
Parkinson Disease, Parkinson Disease Dementia
Interventions
Rivastigmine transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Telerehabilitation Alzheimer's Disease Usability (TADU)

NCT04731311
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
Usability evaluation of BrightGo computerized device for cognitive therapy of individuals with early Alzheimer's Disease
Device
Lead sponsor
Bright Cloud International Corp
Industry
Eligibility
65 Years to 85 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
North Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease

NCT00551161
View directory record Official record
Conditions
Alzheimer Disease
Interventions
memantine
Drug
Lead sponsor
Northwell Health
Other
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 1 Interventional

Rivastigmine as a Treatment for Methamphetamine Dependence

NCT01073319
View directory record Official record
Conditions
Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse
Interventions
Placebo, Rivastigmine
Other · Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Heat on Rivastigmine TDS Products

NCT03915626
View directory record Official record
Conditions
Bioavailability
Interventions
Rivastigmine (RLD) transdermal patch, Rivastigmine (generic) transdermal patch
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems

NCT00988117
View directory record Official record
Conditions
Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Interventions
Rivastigmine Patch 9.5 cm2
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

NCT00623103
View directory record Official record
Conditions
Parkinson's Disease Dementia
Interventions
Rivastigmine capsule, Rivastigmine transdermal patch
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years to 85 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Reseda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2011 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

NCT00766363
View directory record Official record
Conditions
Alzheimer's Disease, Central Nervous System Diseases
Interventions
EVP-6124 (0.1 mg/day), EVP-6124 (0.3 mg/day), EVP-6124 (1.0 mg/day), Comparator: Placebo, Donepezil, Rivastigmine
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
San Diego, California • Hallandale, Florida • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Mild Cognitive Impairment in Parkinson's Disease

NCT01519271
View directory record Official record
Conditions
Parkinson's Disease, Mild Cognitive Impairment
Interventions
Exelon Patch (rivastigmine transdermal system), Placebo Patches
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
40 Years to 85 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Rivastigmine Study in Adolescents With Down Syndrome

NCT01084135
View directory record Official record
Conditions
Down Syndrome
Interventions
Rivastigmine, Liquid Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
10 Years to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2015 · Synced Sep 2, 2026, 5:20 AM EDT
Suspended Phase 2 Interventional

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

NCT06399679
View directory record Official record
Conditions
Anticholinergic Toxicity
Interventions
Rivastigmine, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial

NCT00835159
View directory record Official record
Conditions
Delirium, Postoperative Cognitive Dysfunction
Interventions
Rivastigmine Patch, Placebo Patch
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2015 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 2, 2026, 5:20 AM EDT
Enrolling by invitation Phase 4 Interventional

Quality Improvement and Practice Based Research in Neurology Using the EMR

NCT02670161
View directory record Official record
Conditions
Brain Tumors, Epilepsy, Migraine, Mild Cognitive Impairment, Concussion, Multiple Sclerosis, Neuropathy, Parkinson's, Restless Legs Syndrome, Stroke
Interventions
Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 100 Years
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Sep 2, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available

Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44

NCT00948766
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rivastigmine 4.6 mg/24 h (5 cm^2), Rivastigmine 9.5 mg/24 h (10 cm^2), Rivastigmine 13.3 mg/24 h (15 cm^2), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Tempe, Arizona • Tucson, Arizona • Conway, Arkansas + 84 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 2, 2026, 5:20 AM EDT
Recruiting Early Phase 1 Interventional

Toward a Computationally-Informed, Personalized Treatment for Hallucinations

NCT04366518
View directory record Official record
Conditions
Hallucinations, Auditory, Psychosis
Interventions
Rivastigmine Transdermal System, Scopolamine, Placebo Patch
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 2, 2026, 5:20 AM EDT